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Abstract
Background: Breast to bone metastases frequently induce a ‘‘vicious cycle’’ in which osteoclast mediated bone resorption
and proteolysis results in the release of bone matrix sequestered factors that drive tumor growth. While osteoclasts express
numerous proteinases, analysis of human breast to bone metastases unexpectedly revealed that bone forming osteoblasts
were consistently positive for the proteinase, MMP-2. Given the role of MMP-2 in extracellular matrix degradation and
growth factor/cytokine processing, we tested whether osteoblast derived MMP-2 contributed to the vicious cycle of tumor
progression in the bone microenvironment.
Methodology/Principal Findings: To test our hypothesis, we utilized murine models of the osteolytic tumor-bone
microenvironment in immunocompetent wild type and MMP-2 null mice. In longitudinal studies, we found that host MMP-2
significantly contributed to tumor progression in bone by protecting against apoptosis and promoting cancer cell survival
(caspase-3; immunohistochemistry). Our data also indicate that host MMP-2 contributes to tumor induced osteolysis (mCT,
histomorphometry). Further ex vivo/in vitro experiments with wild type and MMP-2 null osteoclast and osteoblast cultures
identified that 1) the absence of MMP-2 did not have a deleterious effect on osteoclast function (cd11B isolation, osteoclast
differentiation, transwell migration and dentin resorption assay); and 2) that osteoblast derived MMP-2 promoted tumor
survival by regulating the bioavailability of TGFb, a factor critical for cell-cell communication in the bone (ELISA, immunoblot
assay, clonal and soft agar assays).
Conclusion/Significance: Collectively, these studies identify a novel ‘‘mini-vicious cycle’’ between the osteoblast and
metastatic cancer cells that is key for initial tumor survival in the bone microenvironment. In conclusion, the findings of our
study suggest that the targeted inhibition of MMP-2 and/or TGFb would be beneficial for the treatment of bone metastases.
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Introduction
Breast to bone metastasis is a common event during breast
cancer progression with the resultant lesions typically hallmarked
by extensive areas of bone destruction [1]. Despite medical
advances, breast to bone metastases are incurable with treatments
being mainly palliative [2,3]. Only by elucidating the molecular
mechanisms through which breast cancer cells interact with host
cells of the bone microenvironment can new therapies be
generated.
Metastatic breast cancer cells induce osteolytic lesions by high-
jacking the normal bone remodeling process; a finely regulated
biological event comprised of osteoblast mediated bone synthesis
coupled with osteoclast mediated bone resorption [4]. Our current
understanding of the mechanisms underlying tumor-induced
osteolysis is best encapsulated by the concept of the ‘vicious cycle’;
a cycle in which metastatic breast cancer cells secrete factors, such
as parathyroid hormone related peptide (PTHrP) [5], that in turn
stimulate osteoblast expression of factors including receptor
activator of nuclear kappa B ligand (RANKL) that promote
osteoclast recruitment and activation [6]. Osteoclasts mediate
bone destruction by; forming a resorptive seal on the surface of
mineralized bone, lowering the pH to promote de-mineralization
and, secreting cathepsin-K, an acidophilic type I collagenase into
the resorption lacunae [7]. Osteoclast mediated bone resorption
results in the liberation and activation of growth factors such as
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bone matrix [8]. The release of these stored factors in turn can
promote the growth of the tumor cells, thereby completing the
vicious cycle [3]. Osteoblasts are a critical intermediate between
the metastatic breast cancer cells and the osteoclasts and are
therefore essential for the forward momentum of the vicious cycle.
However, little information is available as to whether osteoblasts
can impact tumor behavior directly in vivo.
Prior to osteoclast resorption of the mineralized bone matrix,
bone lining osteoblasts must remodel the non-mineralized osteoid
canopy and retract from the bone surface [9]. The retraction step
requires osteoblast derived proteolytic activity [10,11]. Surpris-
ingly, despite their involvement in the generation of bone matrix,
osteoblasts express a number of proteinases including matrix
metalloproteinases (MMPs) [12,13,14]. While MMPs can degrade
numerous components of the extracellular matrix (ECM), recent
studies have implicated MMPs as important mediators of cell-cell
communication by virtue of their ability to process multiple non-
matrix molecules, such as cytokines and growth factors, to soluble
forms that have either enhanced or attenuated activities [15]. In
assessing MMP expression in human breast-to-bone metastases
and in a mouse model of the osteolytic tumor-bone microenvi-
ronment, we found that MMP-2 was largely localized to
osteoblasts.
Given that osteoblasts express MMP-2 and that MMP-2 is
important for osteoblast function [14,16], we tested whether this
osteoblast derived proteinase impacted the osteolytic vicious cycle.
Surprisingly, we observed that host MMP-2 did not impair
osteoclast behavior but that osteoblast derived MMP-2 was critical
for tumor survival in the bone microenvironment via a mechanism
involving the activation of latent TGFb. Our findings suggest the
presence of a mini-vicious cycle between osteoblasts and the
metastatic cancer cells in the osteolytic tumor-bone microenvi-
ronment that is not dependent on osteoclast activity.
Results
Osteoblasts express MMP-2 in the human and murine
osteolytic tumor-bone microenvironment
Using a rodent model, we previously identified that MMPs were
highly expressed in the tumor-bone microenvironment with
subsequent studies revealing that MMPs such as MMP-7 and
MMP-9 were largely localized to osteoclasts in this setting [17,18].
In contrast, analysis of MMP-2 expression revealed that MMP-2
was localized to both the tumor and stroma of human (n=11) and
murine osteolytic bone metastases (Fig. 1A–B). Of note, osteoblasts
and osteocytes were found to be consistently positive for MMP-2
in human samples and in the control and tumor bearing limbs of
the wild type mice but surprisingly, human and murine osteoclasts
were largely negative for MMP-2 (Fig. 1A–B). Although other
stromal components were positive for MMP-2 we focused our
attention on the osteoblast compartment given their critical role as
an intermediate in the vicious cycle and reports documenting the
contribution of osteoblast derived MMP-2 to bone development
[14,16]. Therefore, we next tested the impact of host MMP-2
ablation on this process in an immunocompetent model of
mammary tumor induced osteolysis.
Host MMP-2 significantly impacts tumor survival in the
bone microenvironment
To determine the contribution of host derived MMP-2 in
mammary tumor growth in bone, two independent mammary
tumor cell lines derived from the transgenic polyoma middle T
antigen (PyMT) model of mammary tumorigenesis, denoted
PyMT-Luc and 17L3C-Luc [19,20], were injected into the tibia
of six week old syngeneic immunocompetent FVB wild type
(n=10) and MMP-2 null (n=10) animals. Upon intratibial
injection, luciferase activity was recorded over time. Quantitation
of the bioluminescent signal from the PyMT-Luc tumor cells
showed a marked decrease in tumor growth rate in MMP-2 null
mice compared to wild type controls from day 3 post-injection
onwards (Fig. 2A–B). Tumors in the MMP-2 null mice were
imaged for at least 25 days and we observed that the
bioluminescent signal never reached the level obtained in the
wild type mice at day 9 (Fig. 2C). These data suggested that host
MMP-2 was important for the initial survival and establishment of
tumor cells in the bone. The observed effect of MMP-2 on tumor
growth was confirmed using the unrelated PyMT derived cell line,
17L3C-Luc (Fig. 2D). These experiments were repeated on five
independent occasions with similar sized groups (n$10 per group)
and similar observations were recorded.
The impact of host MMP-2 on mammary tumor growth in the
bone was analyzed by immunohistochemical staining for Mcm2
(proliferation) and cleaved caspase-3 (apoptosis) at the day 3 time
point since this was consistently the first time point when tumor
growth differences were noted between the wild type and MMP-2
null animals. Surprisingly, no difference in tumor proliferation was
observed between the two groups either at day 3 or at day 6
(Fig. 3A–B). However, in comparison to wild type controls, MMP-
2 null mice showed a significantly higher level of apoptotic tumor
cells at day 3 and this difference persisted to day 6 (Fig. 3C–D).
These data demonstrate for the first time that host MMP-2
impacts tumor growth in the bone microenvironment by
promoting tumor cell survival.
Host MMP-2 contributes to tumor induced osteolysis
The vicious cycle paradigm dictates that increased tumor
growth leads to increased bone resorption and vice versa. Since
decreased tumor growth was observed in MMP-2 null mice, we
next assessed whether there was a concomitant decrease in
osteolysis in the MMP-2 null tumor-bone microenvironment. Of
note, MMP-2 null mice display transient bone phenotypes during
skeletal development [14]. However, analysis of baseline trabec-
ular bone volume by high resolution mCT revealed no differences
between the wild type and MMP-2 null mice at 6 weeks of age
(data not shown). mCT and histomorphometry analyses of the
trabecular bone content was performed on wild type and MMP-2
null mice at the end of the study period (day 9). Tumor bearing
limbs of wild type mice showed a significant decrease in the
trabecular bone volume compared to the MMP-2 null group by
mCT (Fig. 4A) and by histomorphometry (Fig. 4B). No differences
were detected between wild type and MMP-2 null sham injected
control limbs (Fig. 4A–B). Decreased bone resorption in the
MMP-2 null tumor bearing group compared to wild type controls
was further supported by X-ray radiography analysis and by the
number of mature multinucleated TRAcP positive bone lining
osteoclasts (Fig. 4C–D). These results implicate a role for host
derived MMP-2 in mediating mammary tumor induced osteolysis.
MMP-2 deficiency does not inhibit osteoclast precursor
migration or osteoclastogenesis
Although mature osteoclasts were largely negative for MMP-2
expression by immunohistochemistry (Fig. 1), it is possible that
MMP-2 may be expressed in early osteoclast precursors and
therefore, MMP-2 could impact mammary tumor growth-induced
osteolysis by affecting a) migration/recruitment of osteoclast
precursors and/or b) osteoclastogenesis. To address this,
CD11b
+ve myeloid/osteoclast precursors were isolated from the
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using 10% serum revealed no difference between the wild type and
MMP-2 null osteoclast precursors (Fig. 5A). Surprisingly, osteo-
clastogenesis and resorption assays using an equal number of
starter precursor cells revealed MMP-2 null osteoclasts consistently
generated a significantly higher number of functional multinucle-
ated osteoclasts compared to the wild type controls (Fig. 5B–D).
The higher numbers of osteoclasts generated by the MMP-2 null
osteoclast precursors was unexpected given that less mature bone
resorbing osteoclasts were identified in the tumor-bone microen-
vironment of the MMP-2 null mice (Fig. 4D). Importantly
however, our in vitro data, demonstrated that the function of
MMP-2 null osteoclasts was not compromised. Therefore, we
hypothesized that the decreased tumor survival in the MMP-2 null
tumor-bone microenvironment may be osteoblast mediated,
especially given their consistent positivity for MMP-2 expression
in the tumor-bone microenvironment (Fig. 1).
Osteoblast-derived MMP-2 mediates tumor survival
Since osteoblasts express MMP-2 in the tumor-bone microen-
vironment and given our data suggesting host derived MMP-2 was
impacting tumor survival in vivo (Fig. 3C–D), we next tested the
impact of wild type and MMP-2 null primary osteoblasts on tumor
Figure 1. Localization of MMP-2 in the human and murine bone microenvironment. A, Fluorescent TRAcP staining (green) was used to
localize osteoclasts (closed arrow heads) while immunofluorescence was used to localize osteoblast marker osteocalcin and MMP-2 (red) in human
samples of breast to bone metastasis (n=11). DAPI (blue) was used as a nuclear stain. H&E was used to identify tumor-bone morphology. Arrows
indicate osteoblasts while open arrow heads indicate osteocytes. Scale bars represent 50 mm. The localization of MMP-2 in human GCT osteoclasts
(TRAcP positive, brown) was also assessed. B, Immunohistochemistry for MMP-2 (brown) and osteocalcin (OC) in the wild type and MMP-2 null
murine bone and tumor-bone microenvironment. Rabbit IgG was used as a negative control. Arrows indicate osteoblasts while open arrow-heads
indicate osteocytes. Colorimetric TRAcP staining (red) was also used to identify osteoclasts (arrow heads).
doi:10.1371/journal.pone.0029862.g001
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and MMP-2 null osteoblasts revealed no significant morphological
or functional differences with respect to differentiation (Fig. 6A).
Zymography analysis of conditioned media derived from the wild
type and MMP-2 null osteoblast cultures also demonstrated the
presence of latent and active MMP-2 in the wild type cultures only
(Fig. 6A).
Next, we assessed the ability of conditioned media from wild
type and MMP-2 null primary osteoblast cultures to modulate
PyMT-Luc cell growth and survival in vitro using MTT and soft
agar colony formation assays. We found that conditioned media
derived from wild type primary osteoblasts resulted in significantly
higher metabolic activity and in a higher number of tumor
colonies compared to tumor cells incubated with conditioned
media from MMP-2 null osteoblasts (Fig. 7B–C). These data
suggest that an osteoblast derived proteinase, MMP-2, could
influence tumor survival; a conclusion that was in agreement with
our in vivo studies (Fig. 3).
Subsequently, we explored the potential molecular mechanisms
through which osteoblast derived MMP-2 could control tumor
survival. Analysis of the literature revealed TGFb to be a strong
candidate since; a) TGFb is incorporated into the bone matrix and
osteoid canopy by osteoblasts and has been identified as a master
regulator of the vicious cycle via it’s effects on the behavior of the
tumor cells, the osteoblasts themselves and the osteoclasts [21]; b)
MMP-2 has been shown to mediate the processing of the proteins
that sequester TGFb in a latent state, namely the latency
associated peptide (LAP) and the latency binding proteins (LTBP)
-1 and -4 [22,23,24,25,26] and; c) while TGFb has pleiotropic
effects, it has been shown to impact tumor survival in the
mammary gland by protecting against apoptosis and bone marrow
progenitor survival in the bone microenvironment by abrogating
the effects of Fas ligand (FasL) [27,28].
Initially we examined the levels of TGFb by ELISA in the
conditioned media derived from the osteoblast primary cultures.
We found significantly higher levels of TGFb in the conditioned
media derived from the wild type osteoblasts compared to the
levels detected in the conditioned media of the MMP-2 null
osteoblasts and further, that the level of active TGFb could be
significantly enhanced via the addition of recombinant MMP-2
(Fig. 6D). In vivo, TGFb is maintained in a latent form via its
complex with the latency associated peptide (LAP) and members
of the latent TGFb binding protein family (LTBP-1-4). Successive
proteolytic cleavages are required in order to generate active
TGFb [29,30]. MMP-2 has previously been identified as cleaving
LAP and LTBPs-1 and 4. Interestingly, of the LTBP proteins, only
LTBP-3 has been implicated in bone development since LTBP-3
null mice display a distinct cranial phenotype and develop
Figure 2. Host-derived MMP-2 impacts mammary tumor growth in the bone microenvironment. A, Representative timeline of PyMT-Luc
luciferase expression in FVB wild type (WT; n=10) and MMP-2 null (MMP-2
2/2; n=10) mice. Hotter colors indicate areas of increased luciferase
activity. B, Graph represents PyMT-Luc tumor growth over time as assessed by luciferase activity in WT and MMP-2
2/2 animals. C, PyMT-Luc fail to
grow in the MMP-2
2/2 bone microenvironment as assessed over a 25 day period. PyMT-Luc were injected intratibially into syngeneic FVB wild type
(WT; n=10) or MMP-2 null (MMP-2
2/2; n=10) mice. WT mice were euthanized on day 15 due to tumor size. D, 17L3C-Luc, an unrelated cell line
derived from the PyMT model of mammary gland tumorigenesis, was intratibially injected into wild type (WT; n=5) or MMP-2 null (MMP-2
2/2;n=5 )
mice. Luciferase activity was assessed as a measure of tumor growth over a 7-day period. Data are mean 6 SD; Asterisk denotes statistical significance
(p,0.05).
doi:10.1371/journal.pone.0029862.g002
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was capable of processing LTBP-3. Conditioned medium of COS-
7 cells overexpressing the large latent complex of LTBP-3 and
LAP-TGFb was subjected to digestion with recombinant active
MMP-2. The molecular weight of the complex was reduced from
,240 kDa to ,230-220 kDa in the presence of recombinant
active MMP-2, a processing event that is consistent with that
observed for plasmin (Fig. 6E) [35]. Next, we analyzed LTBP-3 in
Figure 3. Host-derived MMP-2 impacts tumor survival in the bone microenvironment. A, Representative photomicrograph of MCM2
positive proliferating (brown) cells in the wild type (WT) and MMP-2 null (MMP-2
2/2) tumor-bone microenvironment. B, Proliferation in the tumor-
bone microenvironment as a function of total cell number was assessed by staining for Mcm2 in tumor bearing tibias of WT and MMP-2 null mice at
day 3 and day 6 post-surgery. C, Representative photomicrograph of caspase-3 positive apoptotic (brown) cells in the wild type (WT) and MMP-2 null
(MMP-2
2/2) tumor-bone microenvironment. D, Apoptosis in the tumor-bone microenvironment as a function of total cell number was assessed by
staining for cleaved caspase-3 at day 3 and day 6 post surgery. Data are mean 6 SD; n.s. implies a non-significant p value (p.0.05).
doi:10.1371/journal.pone.0029862.g003
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primary osteoblast cultures. A comparison of conditioned media,
normalized for total protein content, identified higher levels of
LTBP-3 in the conditioned media derived from the MMP-2
2/2
osteoblasts compared to the wild type control (Fig. 6F). Further-
more, the addition of recombinant MMP-2 (100 ng/ml for one
hour at 37uC) to conditioned media (equally loaded for LTBP-3
using densitometry) demonstrated that LTBP-3 could be processed
further (Fig. 6F). These data suggest LTPB-3 is an MMP-2
substrate, and support our hypothesis that osteoblast derived
MMP-2 can mediate the activation of TGFb.
Osteoblast derived MMP-2 mediates tumor survival via
TGFb
To test whether TGFb could mediate tumor survival, we
initially used a soft agar colony formation assay and found that
treatment of the tumor cells with recombinant active TGFb
significantly increased the number of colonies compared to control
conditions (Fig. 7A). To test whether TGFb was the principal
molecule in the osteoblast conditioned media through which
MMP-2 impacted tumor survival, we utilized a TGFb neutralizing
antibody (2G7). Addition of the neutralizing TGFb antibody to the
conditioned media harvested from wild type osteoblasts signifi-
cantly reduced tumor survival compared to IgG controls in 2D
(plastic) and soft agar colony formation assays (Fig. 7B–C). We
observed that the addition of the neutralizing TGFb antibody to
the MMP-2 null osteoblast conditioned media had no impact on
tumor survival (Fig. 7B–C), while the addition of recombinant
MMP-2 to conditioned media from MMP-2 null primary
osteoblasts rescued the tumor survival phenotype (Fig. 7C). In
the colony formation assays, no difference was observed in the
average size of the colonies, suggesting that the absence of MMP-2
in osteoblasts affects tumor survival but not tumor proliferation, a
conclusion that is in agreement with our in vivo data (Fig. 7D). For
the first time, these data demonstrate that an osteoblast derived
proteinase, MMP-2, can impact tumor survival.
Host MMP-2 impacts TGFb bioavailability and tumor
survival in vivo
Having demonstrated that osteoblast derived MMP-2 mediated
the activation of TGFb and tumor survival in vitro; we determined
the relevance of the mechanism in the in vivo osteolytic tumor-bone
microenvironment. We found that lysates, normalized for total
protein content, derived from the wild type tumor injected tibias
had significantly higher levels of active TGFb compared to the
MMP-2 null tumor bone lysates (Fig. 8A). Further, analysis of
downstream TGFb signaling revealed that the ratio of phospho-
smad2 to total smad2 was also significantly higher in the wild type
tumor-bone lysates compared to the MMP-2 null tumor bone
lysates (Fig. 8B). We also examined the levels of phospho-AKT as
a general readout for cell survival in the tumor bone microenvi-
ronment [27]. Consistent with our conclusion that TGFb was
promoting cell survival, we observed significantly higher ratios of
phospho AKT to total AKT in the tumor-bone lysates derived
from the wild type mice compared to the MMP-2 null mice
(Fig. 8B). Collectively, these data support our overarching
hypothesis that an osteoblast derived proteinase, MMP-2, is key
for mediating for TGFb activation and tumor survival in vivo.
Furthermore, our studies reveal a novel interplay between the
tumor cells and osteoblasts that is independent of the osteoclast
compartment and suggests the presence of a mini-vicious cycle in
the tumor-bone microenvironment that is critical for initial tumor
survival and establishment (Fig. 8C).
Discussion
Breast to bone metastasis is an incurable disease that commonly
affects women with late stage breast cancer [1]. Lytic bone lesions
cause severe complications that greatly impact the patient’s quality
of life. Surgery, radiotherapy and chemotherapy with bisphos-
phonates are tools currently employed to tackle the disease yet
these treatments are mainly palliative rather than curative [2,3].
Therefore, identifying the molecular mechanisms underlying cell-
cell communication in the tumor-bone microenvironment is key
for the development of therapies that can treat and ultimately cure
the disease.
The osteoblast-tumor mini-vicious cycle is mediated by
MMP-2 and TGFb
To date, the majority of studies examining the breast to bone
metastatic microenvironment have focused on the final step of the
vicious cycle, i.e. how osteoclasts are recruited and activated to the
tumor-bone microenvironment to induce bone destruction.
Tumor stimulation of osteoblasts to secrete osteoclastogenic
factors is critical in mediating osteoclastogenesis in order to
complete the vicious cycle [3]. However, little emphasis has been
placed on whether the osteoblasts themselves can impact tumor
behavior in the in vivo bone-microenvironment. Our studies show
for the first time that an osteoblast derived proteinase, MMP-2,
can significantly impact on tumor survival and establishment in
the mammary tumor-bone microenvironment. Furthermore, we
suggest that MMP-2 processing of the factors that sequester TGFb
in a latent state is the principal mechanism underlying our
observations. Based on these data, we posit the existence of a
vicious mini-cycle in the context of the larger osteolytic vicious
cycle in which the osteoblast is critical for mediating the survival
and establishment of the tumor cells in the bone microenviron-
ment (Fig. 8C). Our observations support this conclusion since; a)
tumor growth is significantly attenuated at an early time point in
MMP-2 null animals (Fig. 2–3); b) the absence of MMP-2 does not
negatively impact osteoclast migration or function (Fig. 5); c)
conditioned media derived from the MMP-2 null osteoblasts failed
to promote tumor survival compared to conditioned media from
wild type osteoblasts (Fig. 6–7); d) the addition of exogenous
MMP-2 to the MMP-2 null osteoblasts resulted in an increase in
active TGFb that subsequently promoted tumor survival (Fig. 6)
and; e) the use of a TGFb neutralizing antibody blocked the
survival effect observed with the wild type osteoblast conditioned
media (Fig. 7).
Figure 4. Tumor induced osteolysis is controlled by host MMP-2. A, Representative mCT scans of trabecular bone from tumor bearing and
sham injected limbs of wild type (WT) and MMP-2 null (MMP-2
2/2) mice at day 9. Graph illustrates ratio of bone volume to total volume (BV/TV). B,
Representative H&E stained photomicrographs of tumor bearing tibias from WT and MMP-2
2/2 mice. Scale bars represent 1 mm. Graph represents
the BV/TV ratio. C, Representative radiographic images from tumor injected WT and MMP-2
2/2 animals at day 9. Arrow indicates lytic tumor lesions in
the wild type group. Graph represents the tumor volume (TuV) over total volume (TV) ratio. D, Representative TRAcP stained photomicrographs of
tumor injected WT and MMP-2
2/2 animals at day 9. Scale bar represents 50 mm. Graph indicates the number of osteoclasts/mm of trabecular bone.
Data are mean 6 SD. Asterisk denotes that p,0.05.
doi:10.1371/journal.pone.0029862.g004
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and can activate other proteinases [36]. Therefore, MMP-2 could
potentially contribute to tumor progression via other mechanisms
by processing molecules such as insulin like growth factor binding
proteins (IGF-BPs), ephrin receptors and growth factors that
contribute to angiogenesis [37,38,39,40,41]. However, our in vitro
and in vivo studies suggest that MMP-2 processing of TGFb is the
principal mechanism underlying our observations. Furthermore,
since the MMP-2 null animals used in the current study were
systemically null for MMP-2, it is possible that MMP-2 derived
from cellular sources other than the osteoblasts could regulate
TGFb activation. For example, the metastatic cancer cells in a
number of human breast to bone metastases analyzed in our study
were positive for MMP-2 and previously, the forced overexpres-
sion of MMP-2 or the endogenous tissue inhibitor of metallopro-
teinase-2 (TIMP-2) in cancer cells has been shown to promote or
protect against tumor induced bone destruction respectively
[42,43]. Whether these effects are mediated via the control of
TGFb bioavailability is not known. These observations docu-
menting the contribution of MMP-2 to cancer progression are not
limited to bone since other studies have defined roles for MMP-2
in primary and metastatic tumor progression [41,42]. Therefore,
the generation of highly selective MMP-2 inhibitors could be
useful for the treatment of a number of cancers including bone
metastases. To this end, studies show that an MMP-2/-9 selective
inhibitor, SB-3CT, significantly halts tumor progression in the
bone [44]. We and others have previously shown that the ablation
of host MMP-9 has a minimal impact on tumor/growth or tumor
induced osteolysis [18,45] thus implicating the importance of
MMP-2 in the progression of bone metastases.
MMP-2 processing of LTBP-3 potentiates TGFb activation
Multiple studies have focused on the role of TGFb in the tumor-
bone microenvironment but often these studies have not examined
the mechanisms of TGFb activation. TGFb is sequestered in a
latency complex comprised of LAP and LTBPs. These complexes
must be sequentially processed in order to generate active TGFb
[46,47,48,49]. Interestingly, LTBP-3 null mice demonstrate
altered skull development, osteoarthritis and osteopetrosis, defects
that phenocopy those observed in animals with impaired TGFb
signaling in osteoblasts [50]. Our study identifies for the first time
that osteoblast-derived MMP-2 is capable of processing LTBP-3
(Fig. 6E), and based on studies identifying MMP-2 as being able to
process LAP-TGFb [26,51], we posit that MMP-2 subsequently
cleaves LAP-TGFb to release active TGFb (Fig. 8C). Other
members of the LTBP family such as LTBP-1 and 4 are MMP-2
substrates and LTBP-1 has been shown impact osteoblast
mediated bone formation [24,36,47]. However, in mice, LTBP-1
deficiency results in a heart defect while LTBP-4 deficiency results
in impaired lung development and colon tumorigenesis
[52,53,54,55] suggesting that LTBP-3 may be a key regulator of
TGFb bioavailability in the bone microenvironment. Based on our
preliminary observations regarding MMP-2 processing of LTBP-3,
we hypothesize that osteoblast derived MMP-2 is a key mediator
of TGFb activation in the tumor-bone microenvironment. It is
important to note that MMP-9 and plasmin are also capable of
processing TGFb latency complexes thus potentially explaining
why residual levels of active TGFb were identified in the
conditioned media derived from MMP-2 null osteoblasts
(Fig. 6D) and also why TGFb neutralizing antibody treatment
with MMP-2 null conditioned media could further reduce the
number of tumor colonies (Fig. 7B). However, given the data
presented herein, plasmin and MMP-9 do not appear to
compensate for the loss of MMP-2. In addition, while MMP-2
can directly mediate the activation of TGFb, it may also initiate
proteolytic cascades that ultimately lead to TGFb activation
[56,57]. Conversely, MMP-2 is secreted in an inactive state and
therefore, proteinases that can activate MMP-2 are indirectly
Figure 5. Absence of host MMP-2 does not impair osteoclast
precursor function. A, Quantitative analysis of isolated wild type (WT)
and MMP-2 null (MMP-2
2/2) CD11b
+ve osteoclast precursor migration
to 10% serum or control serum free media. B, Analysis of the
osteoclastogenic capability of WT or MMP-2
2/2 osteoclast precursors.
Arrows indicate TRAcP positive (red) multinucleated (blue) osteoclasts.
Scale bars represent 50 mm. C, Analysis of the number of WT and MMP-
2
2/2 mature osteoclasts formed/well in each group (n$3/group). D, Pit
formation assay on dentin discs to test the functionality of mature WT
and MMP-2
2/2 osteoclasts. Asterisk denotes that p,0.05 while p=n.s.
denotes non-significant p values.
doi:10.1371/journal.pone.0029862.g005
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29862Figure 6. Osteoblast-derived MMP-2 controls TGF-b bioavailability. A, Representative phase contrast photomicrographs of isolated wild
type (WT) and MMP-2 null (MMP-2
2/2) primary osteoblast morphology. Osteoblasts were characterized by differentiation in the presence or absence
of OGM and measuring alkaline phosphatase activity. Asterisk denotes statistical significance (p,0.05) between the OGM and the respective control
treated groups. Conditioned media derived from wild type (WT CM) and MMP-2 null (MMP-2
2/2 CM) primary osteoblasts was also assessed for the
presence of MMP-2 using gelatin zymography. Arrow denotes latent MMP-2 while arrow head denotes active MMP-2. HT1080, a human firbosarcoma
cell line was used as a positive control for MMP-2. B and C, PyMT-Luc cells were treated with conditioned media from wild type (WT CM) or MMP-2
null (MMP-2
2/2 CM) osteoblasts. The metabolic activity of PyMT-Luc cells treated with WT CM or MMP-2
2/2 CM was assessed by MTT assay (B) and
survival was determined by soft agar colony formation (C). D, Levels of TGFb in WT and MMP-2
2/2CM were assessed by ELISA. Changes in TGFb
levels were also assessed after the addition of recombinant MMP-2 (rMMP-2; 100 ng/ml CM for 3 hours at 37uC). E, The ability of MMP-2 (100 ng
recombinant MMP-2/ml CM 3 hours at 37uC) to process LTBP-3 derived from transfected COS-7 cells was assessed by immunoblot as described [32].
Plasmin (1 mg/ml of CM 1 hour at 37uC) was used as a positive control. F, LTBP-3 levels and the impact of recombinant MMP-2 on LTBP-3 processing
in the CM derived from WT and MMP-2
2/2 osteoblasts was determined by immunoblot analysis. MW is indicated by 230 kDa. Arrow indicates full
length LTBP-3.
doi:10.1371/journal.pone.0029862.g006
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For example, MMP-14 has been shown to regulate MMP-2
activation and given the role of MMP-14 in skeletal development it
is highly likely that osteoblast derived MMP-14 may impact the
osteolytic vicious cycle by controlling MMP-2 activity [12,58].
MMP-2 and TGFb effects on the osteoclast compartment
of the vicious cycle
Our data demonstrate that osteoblast derived MMP-2 regula-
tion of TGFb bioavailability is critical for promoting tumor cell
survival. While osteoclast precursors derived from MMP-2 null
mice have no deficiencies with respect to migration and
osteoclastogenesis, we cannot rule out that active TGFb generated
by osteoblasts may also have an effect on the osteoclast
compartment of the vicious cycle. TGFb has been shown to have
differential effects on osteoclast behavior ranging from promoting
osteoclast survival to osteoclastogenesis while some reports
demonstrate that TGFb can induce osteoclast apoptosis [59,60].
These differential effects of TGFb on osteoclast behavior may be
dependent on the experimental conditions used in various studies.
Thus, the precise role for TGFb in regulating osteoclast behavior
in vivo currently remains to be determined.
Surprisingly, our studies have shown that although MMP-2 does
not appear to be expressed by mature osteoclasts, MMP-2 null
osteoclast precursors undergo osteoclastogenesis more efficiently
than wild type controls. This result is in contrast to previous
reports showing that osteoclastogenesis is significantly attenuated
in MMP-2 null bone marrow cultures [16]. These opposing
conclusions may be due to the purity of the starting cultures
(CD11b
+ve myeloid cells vs. whole bone marrow isolates) and
Figure 7. MMP-2 mediates tumor survival in a TGFb dependent manner. A, Tumor survival in the presence of 1 ng/ml recombinant TGFb
was assessed by soft agar colony formation assay. B, The number of PyMT-Luc colonies formed in response to 10 days of treatment with control
media (5% serum containing aMEM) or conditioned media derived from wild type or MMP-2 null osteoblasts was analyzed in a 2D (plastic) assay
(non-treated group). Under similar conditions the impact of TGFb inhibition was also determined (matched isotype antibody was added to control
wells). Differences are significant as assessed by ANOVA. C, The effects of blocking TGFb in the CM derived from WT and MMP-2
2/2 osteoblasts was
determined by soft agar colony formation assay. Data are mean 6 SD. Asterisk indicates p,0.05 and n.s indicates non significance. Double asterisk
denotes that the addition of recombinant MMP-2 to MMP-2
2/2 CM significantly enhances tumor survival compared to MMP-2
2/2 CM alone. D,
Osteoblast-derived MMP-2 and TGF-b mediate tumor survival without impacting colony size. Using a soft agar colony formation assay, no difference
in colony size was detected between the various treatment conditions. Data are mean 6 SD.
doi:10.1371/journal.pone.0029862.g007
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osteoblasts, leukocytes and mesenchymal progenitor cells in
regulating osteoclastogenesis. Interestingly, humans with a defi-
ciency in MMP-2 also have heightened areas of osteolysis and it is
tempting to speculate that MMP-2 activation of TGFb may be
important in controlling osteoclast activity in this setting [61].
In conclusion, this study demonstrates how an osteoblast
derived proteinase, MMP-2, can significantly impact mammary
tumor growth in the bone microenvironment by enhancing tumor
survival suggesting the presence of a mini-vicious cycle between
the cancer cells and osteoblasts that is independent of osteoclast
activity. We suggest that MMP-2 contributes to tumor survival by
controlling the bioavailability of TGFb via the processing of
LTBPs, such as LTBP-3. Finally, our results support the rationale
for the development of selective MMP inhibitors and/or the use of
therapies that interfere with TGFb signaling for the treatment of
osteolytic breast to bone metastases.
Materials and Methods
Ethics Statement
All experiments involving animals and, primary cell lines
isolated from animals (osteoclasts and osteoblasts), were conducted
after review and institutional animal care and use committee
(IACUC) approval by the office of animal welfare at Vanderbilt
University (M/10/277 to CCL) and the Moffitt Cancer Center
(3886R to CCL). De-identified human samples of frank osteolytic
breast to bone metastasis (n=11) and giant cell tumor (GCT,
n=1) were collected by curettage with IRB approval (IRB
#40194) at Vanderbilt University from 2005 to 2010 with the
patient’s written consent.
Reagents
Two different syngeneic FVB mammary tumor cell lines derived
from the mammary tumor virus (MMTV) long terminal repeat-
polyoma middle-T antigen (MMTV-PyMT) model of mammary
tumorigenesis were isolated in our laboratory and maintained as
previously described [19,20]. These tumor cells lines were tagged
with a luciferase reporter gene and designated, PyMT-Luc and
17L3C-Luc. All reagents were obtained from Sigma-Aldrich (St.
Louis, MO, USA) except where specified.
Histology
Fresh human breast-to-bone metastases and tumor and sham
injected mouse tibiae were fixed overnight in 10% buffered
formalin and decalcified for 3 weeks in 14% EDTA at pH 7.4 at
4uC with changes every three days. Tissues were dehydrated
through ethanols, embedded in paraffin and 5 mm thick sections
were cut. For MMP-2 localization (anti-MMP-2, AB37150,
Abcam, Cambridge MA, USA), osteocalcin (anti-osteocalcin, sc-
30044, Santa-Cruz Biotechnology, Santa-Cruz, CA, USA) a
marker for used for osteoblasts [62], tumor proliferation (anti-
Mcm2, AB31159, Abcam) and tumor apoptosis (anti-Caspase-3,
#9662, Cell Signaling Technology, Danvers, MA, USA), the
following technique was employed. Sections were rehydrated
through a series of ethanols and then washed in Tris buffered
saline with Tween-20 (TBST) (TBS; 10 mM Tris at pH 7.4,
150 mM NaCl with Tween-20 (0.05%). Following washing in
TBS, tissue sections were blocked using standard blocking criteria
for 1 hour at room temperature. MMP-2 (1:150 dilution),
osteocalcin (1:100), Mcm2 (1:200 dilution) and cleaved caspase-3
(1:400 dilution) antibodies in blocking solution were added to the
tissue sections and incubated overnight at 4uC. The appropriate
IgG control antibodies were used for each antibody to ensure
Figure 8. Osteoblast-derived MMP-2 impacts TGFb activation
and tumor survival in the in vivo tumor-bone microenviron-
ment. A, The levels of TGFb in normalized tumor-bone lysates derived
from WT and MMP-2
2/2 tumor or sham injected tibias was assessed by
ELISA. B, Representative immunoblots for phospho-SMAD (pSMAD2),
total smad2 (SMAD2), phospho-AKT (pAKT), total AKT (AKT) and actin
(loading control) in the tumor-bone lysates derived from WT and MMP-
2
2/2 mice. Densitometry on immunoblots generated from tumor bone
lysates of at least 5 animals per group was used to generate graphs of
the ratio of pSMAD2/SMAD2 and pAKT/AKT. Data are mean 6 SD. *,
p,0.05. C, Osteoblast derived MMP-2 controls TGFb activation and
mammary survival in the tumor-bone microenvironment. (1) Tumor
derived signals induce osteoblast retraction from mineralized matrix
and the resorption of the non-mineralized osteoid canopy. (2) We posit
that MMP-2 processing of the factors that sequester TGFb in a latent
state such as LTBP-3 and LAP initiates TGFb activation. (3) Our data
show that the activation of TGFb by osteoblast derived MMP-2
mediates tumor survival and we hypothesize this mini-vicious cycle is
essential for the establishment of the traditional vicious cycle of tumor
induced osteolysis.
doi:10.1371/journal.pone.0029862.g008
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addition of a species-specific secondary biotinylated IgG antibody
(Vector Laboratories, Burlingame, CA, USA) diluted 1:1,000 in
blocking solution for 1 hour at room temperature. Labeled cells
were visualized using an avidin-biotin peroxidase complex
(Vectastain ABC kit, Vector Laboratories) and 3,39 –Diamino-
benzidine tetrahydrochloride substrate. Sections were counter-
stained with hematoxylin prior to dehydration through ethanols
and permanently mounted.
Tartrate-resistant acid phosphatase (TRAcP), a marker of
mature osteoclasts, was detected using a colorimetric kit according
to the manufacturer’s instructions (Kit 387-A, Sigma-Aldrich) or
via immunohistochemistry as described (18-0199, Invitrogen).
Gross anatomy of the mouse tibiae was assessed by hematoxylin
and eosin (H&E) staining. Immunofluorescent localization of
MMP-2, osteocalcin and TRAcP assays were performed as
previously described [18,63].
Intratibial injection and in vivo quantitation of tumor
growth
PyMT-Luc or 17L3C-Luc tumor cells (2610
5)i na1 0 ml
volume of sterile phosphate buffered saline (PBS) were injected
into the tibia of anesthetized immunocompetent 6 week old female
mice that were wild type or null for MMP-2. The contralateral
limb was injected with 10 ml of PBS alone and acted as a sham
injected control for changes in the bone due to the surgical
procedure. The IVIS
TM system (Caliper Life Sciences, Hopkinton,
MA) was used to detect luminescence from the PyMT-Luc and
17L3C-Luc tumor cells after intratibial injection. Firefly luciferin
(120 mg/kg in sterile PBS, Gold Biotechnology, Inc., St. Louis,
MO) was delivered retro-orbitally 2 minutes prior imaging. Mice
were imaged at 24 hours and every 3 days after surgery. Living
Image
TM software (Caliper Life Sciences) was used to quantify the
luminescence intensity in the tumor-bearing limb over time. For
the histology and histomorphometry studies, mice were sacrificed
at 9 days post-surgery which was previously determined to be the
time point prior to tumor breach of the cortical bone by PyMT-
Luc in wild type control mice [19]. For immunohistochemical
staining, mice injected with tumor cells were collected at described
time points and both tumor bearing and control tibias were
collected. All animal studies were independently repeated on five
independent occasions.
Micro computed tomography (mCT), x-ray radiography
and histomorphometric analyses
For gross analysis of trabecular bone volume, formalin fixed
tibiae were scanned at an isotropic voxel size of 12 mm using a
microCT40 (SCANCO Medical, Bruttisellen, Switzerland). The
tissue volume (TV) was derived from generating a contour around
the metaphyseal trabecular bone that excluded the cortices. The
area of measurement began at least 0.2 mm below the growth
plate and was extended by 0.12 mm. The bone volume (BV)
included all bone tissue that had a material density greater than
438.7 mgHA/cm
3. These analyses allowed for the calculation of
the BV/TV ratio. The same threshold setting for bone tissue was
used for all samples. Radiographic images (Faxitron X-ray Corp,
Lincolnshire, IL, USA) were obtained using an energy of 35 kV
and an exposure time of 8 seconds. The tumor volume (TuV) was
calculated as a function of the total tissue volume (TV) of the tibial
medullary canal using MetamorphH software (Molecular Devices,
Sunnyvale, CA, USA).
For histomorphometry, three non-serial sections of tumor
bearing and sham injected hind limbs were H&E stained to assess
the BV/TV ratio or with TRAcP to assess osteoclast number per
mm bone at the tumor bone interface using MetamorphH software
(Molecular Devices).
Isolation of osteoclast precursor cells and primary
osteoblasts
All primary cell lines were collected from mice with IACUC
approval (Vanderbilt University (CCL-M/10/277) and Moffitt
Cancer Center (CCL-3886R)). For the collection of osteoclast
precursor cells, the bone marrow from the tibias and femurs of 6
week-old wild type and MMP-2 null mice were collected by
flushing the cells with 1 ml of cold 16PBS using a 25G
5/8 gauge
needle. Isolated cells were centrifuged at 1,000 rpm and rinsed
with 1 ml of 16 PBS. CD11
+ve cells were then isolated using a
MacsH separation protocol as per the manufacturer’s directions
(Cat No. 130-049-601, Miltenyi Biotec, Auburn, CA, USA) and
plated in a-MEM and 10% fetal bovine serum (Cat. No. 0500A,
Atlas Biologicals, Fort Collins, CO, USA), 100 mg/ml penicillin/
streptomycin with 250 UG/ml fungizone (Invitrogen) for migra-
tion and differentiation assays.
For osteoblast primary cultures, calvaria from wild type or
MMP-2 null 3 day-old neonates were isolated in cold sterile 16
PBS buffer. Calvaria were then subjected to three repetitive
digestions (15 min, 30 min and 1 hour incubations) in digestion
buffer (a-MEM, Cat. No. 12571, 0.025% trypsin, Cat. No. 25200,
100 mg/ml penicillin/streptomycin Cat. No. 15070-063,
250 UG/ml fungizone Cat. No. 15290-018, Invitrogen and
10 mg/ml collagenase P, Cat. No. 11213857001, Roche, Basel,
Switzerland) at 37uC with vigorous shaking every 15 min. Isolated
primary cells were then maintained in a-MEM and 10% fetal
bovine serum (Atlas Biologicals). Primary osteoblasts were plated
at a density of 2610
5 cells/well in 6 well-plates and 24 h after
seeding; cells were cultured in serum-free a-MEM. After 24 h,
conditioned media was collected, centrifuged at 1100 rpm to
remove cellular debris and used for the MTT and soft agar colony
formation assays described below.
Migration assay of osteoclast precursor cells
CD11b
+ve cells were plated at a density of 10
5 cells/well in the
upper well of a transwell (5 mm pore size, Corning Inc., Corning,
NY, USA) in 500 ml of serum free a-MEM media. Cells were
allowed to migrate towards the lower well of the transwell (1 ml of
chemotactic gradient (10% serum-a-MEM) or serum-free media
as control) for 5 hours at 37uC. CD11b
+ve that migrated through
the membrane were harvested in the lower well and counted.
Experiments were performed in triplicate.
Differentiation of osteoclast precursor cell assay
CD11b
+ve cells isolated from 6 week-old wild type and MMP-2
null bone marrow cells were plated in 48 well plates in 10% serum-
a-MEM media at a density of 5610
5 cells/well. The following
day, cells were treated with 75 ng/ml RANKL (R&D Systems,
Minneapolis, MN, USA) and 30 ng/ml M-CSF (R&D Systems) in
500 ml of 10% serum-a-MEM media. Media was changed every 3
days for a 15 day period. At the end of the assay, cells were fixed in
ice-cold methanol and stained using a colorimetric TRAcP kit
(Sigma-Aldrich) and counter stained in hematoxylin. Multinucle-
ated (more than 3 nuclei) TRAcP cells were counted in eight
random fields acquired using a 106microscopic objective for each
condition. Experiments were performed in quadruplicate. For
osteoclast functionality assays, dentin discs were removed from
culture and sonicated for 2 min in 5 ml of 0.25 M ammonium
hydroxide to remove cells. The discs were then stained for 5 min
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number of pits formed per disc was counted using reflective light
microscopy.
Osteoblast characterization and zymography
Primary osteoblasts were cultured for two weeks in the presence
or absence of osteogenic media (OGM; 10 mM biglycerol
phosphate, 50 mM ascorbic acid, 25 ng/ml bone morphogenetic
protein-2 (BMP-2; R&D Systems) in 10% serum containing alpha
MEM). After 2 weeks of incubation, the cells were assessed for
alkaline phosphatase activity as a readout for differentiation.
Osteoblast cell lysates were generated using standard lysis buffers.
The total protein content in the cells was measured by BCA assay
and alkaline phosphatase activity was measured in normalized
samples using p-nitrophenyl phosphate (p-NPP; Pierce, Rockford,
IL, USA) in a 1 M diethanolamine buffer at pH 9.8. Absorbance
in control and OGM treated cells was measured at 405 nm.
For analysis of MMP-2 enzymatic activity, wild type and MMP-
2 null primary osteoblast cultures were seeded at a concentration
of 5610
5 cells per 60 mm dish. After 48 hours incubation, the cells
were incubated in serum free media for 3 hours. Afterwards, the
cells were rinsed in 16PBS and incubated for 24 hours in 2.5 ml
of serum free media. Subsequently, the total protein in the
collected conditioned media was measured by BCA (Pierce) assay
and the samples were normalized for total protein concentration
prior to zymography (25 mg total protein per well). For gelatin
zymography, gelatin was added to SDS resolving gels to a final
concentration of 1 mg/ml and equal amounts of total protein were
run under non-reducing conditions. After electrophoresis the gels
were washed in 2.5% solution of Triton-X-100 followed by
overnight incubation in substrate buffer (50 mM Tris-HCL,
pH 7.4 containing 5 mM CaCl2). The following day, the gels
were staining in a 5 mg/ml coomassie brilliant blue solution (1
part acetic acid: 3 parts isopropyl alcohol: 6 parts water). The gels
were then destained in water and digitized.
MTT Assay
Quantitation of viable PyMT-Luc cells treated with conditioned
media from primary osteoblast wild-type or MMP-2 null mice was
assessed by tetrazolium-based colorimetric MTT assay (Cat.
No. G5421, Promega, Madison, WI, USA). Tumor cells were
plated in 96-well plates at a density of 1000 cells/well and 24 h
after seeding, cells were treated with 100 ml either serum-free or
conditioned media from primary osteoblasts isolated from either
wild type or MMP-2 null mice. After 24 h of treatment, 20 mlo f
MTS was added to each well, and the reactions were allowed to
run for 3 h at 37uC. Spectrophotometric absorbance of each
sample was measured at 490 nm using a MRX revelation
microplate reader (Dynex Technologies, Chantilly, VA). Experi-
ments were performed in quadruplicate.
Expression and enzymatic processing assays
COS-7 cells were transiently transfected with a full length
LTBP-3 cDNA construct and human TGFb1 cDNA (kindly
provided by Dr David Rifkin, [32] using Superfect kit (QIAGEN,
Carlsbad, CA, USA). COS-7 cells were plated at a density of 10
5
cells/well in a 6 well plate the day prior the transfection. Cells
were then incubated in transfection mix (30 ml of Superfect
reagent, 0.5 mg of each constructs and 500 ml of DMEM and 10%
fetal bovine serum) overnight. The next day, transfected COS-7
cells were incubated for 48 hours in serum starved DMEM media.
The conditioned media was then incubated for 3 hours in
presence of 300 ng of recombinant human MMP-2 or for 1 hour
in presence of 1 mg plasmin (Sigma-Aldrich) as a positive control
[35]. Samples were then analyzed by immunoblotting for LTBP-3
as described below.
Immunoblotting and ELISA
Tumor and sham injected tibias from wild type or MMP null
animals were harvested 3 days post-injection and flash frozen in
liquid nitrogen. Tissue homogenates were generated by mortar
and pestle and total protein was subsequently extracted using a
standard protein lysis buffer (0.1% sodium dodecyl sulfate, 0.5%
sodium deoxycholate, 1% triton X100, 10 mM Tris pH 7.5,
150 mM NaCl) containing a complete proteinase inhibitor
cocktail (Roche) and phosphatase inhibitor cocktails (Sigma-
Aldrich). Protein concentration in isolated samples was quantitated
using a bicinchoninic acid (BCA) assay as per manufacturer’s
instructions (Pierce). Equal concentrations of total protein were
loaded on to a denaturing 8% SDS-PAGE gel. The blots were
then panned with antibodies directed to, phospho Smad2
(Millipore), total Smad2 (Cat. No. 3102, Cell Signaling Technol-
ogy), phospho AKT and AKT (Cell Signaling Technology) and
actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). All
antibodies were diluted 1: 1,000 in 5% BSA in 16TBST (TBS
with 0.05% Tween 20) overnight with rocking at 4uC. For latent
binding protein-3 (LTBP-3) immunoblotting, equal amounts of
protein were loaded on 6% SDS-PAGE non-denaturing gels. Blots
were then incubated anti-LTBP-3 antibodies (anti-L3C [32])
diluted 1: 1,000 in standard blocking solution (5% milk in 16
TBS) overnight at 4uC with rocking. The following day, blots were
washed extensively with 16TBST prior to the addition of a
secondary infra-red labeled antibody (1: 5,000 dilution in
16TBST, Rockland Inc., Gilbertsville, PA, USA) for 1 hour at
room temperature with rocking, in the dark. After washing in
16TBST, blots were developed and bands of interest were
quantitated using the Odyssey system (LI-COR Biosciences,
Lincoln, NE, USA). ELISA assays for TGFb (Cat. No. MB100B,
R&D Systems) were performed according to the manufacturer’s
instructions.
Soft agar colony formation assay
PyMT-Luc cells were plated at a density of 1.5610
3 cells/well
in 24 well-plates in soft agar containing a-MEM, 5% fetal bovine
serum, 0.7% agarose (Cat. No. BP164, Fisher Scientific, Fair
Lawn, NJ, USA). Subsequent to plating, tumor cells were treated
with 400 ml of either with 5% serum a-MEM or conditioned
media derived from either wild type or MMP-2 null primary
osteoblasts supplemented with 5% serum. Experimental conditions
also included the addition of the TGFb neutralization antibody
2G7 at 10 mg/ml or an IgG2b control antibody [64] in the
presence or absence of 100 ng/ml recombinant active MMP-2
(Cat. No. PF023, EMD Biosciences, San Diego, CA). Soft agar
PyMT-Luc colony formation assays were also performed with
1 ng/ml TGFb in 5% serum a-MEM. The media with various
experimental conditions was changed every 3 days. After 10 days
of culture, cells were stained overnight with 0.1 mg/ml p-
iodonitrotetrazolium (Cat. No. I-8377, Sigma-Aldrich). Numbers
of colonies and average diameter of the colonies for each condition
were measured on 1006 photomicrographs and analyzed using
Meta morph Imaging Software (Molecular Devices). Experiments
were performed in quadruplicate.
2D-Colony formation assay
PyMT-Luc were seeded into 24 well plates (50 cells per well).
The cells were allowed to attach and then treated with 400 mlo fa-
MEM (Control) or conditioned media derived from either wild
type or MMP-2 null primary osteoblasts all supplemented with 5%
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TGFb neutralization antibody 2G7 at 10 mg/ml or an IgG2b
control antibody. The media was changed every 3 days for 10
days. To assess colony formation, wells were rinsed in 16PBS then
the colonies were fixed and stained in a solution containing 6%
glutaraldehyde and 0.5% crystal violet for 30 minutes at room
temperature. The wells were rinsed twice in dH2O prior to drying
and counting the total number of colonies per well.
Statistical analyses
Statistical analyses were performed using Student’s t Test or
ANOVA where appropriate using GraphPad Prism (GraphPad
Software, Inc., La Jolla, CA, USA). A value of p,0.05 was
considered significant. Data are presented as mean 6 standard
deviation (SD).
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